Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity

Journal of Pharmaceutical Sciences

Volumn 103, Issue 8, 2014, Pages 2315-2322

  Carlson, Lisa Janssen ^a   Cote, Brianna ^a   Alani, Adam Wg ^b   Rao, Deepa A ^a  

^a PACIFIC UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

cancer chemotherapy; nanoparticles; natural products; physicochemical; polymeric drug delivery systems; toxicity

Indexed keywords

CASPASE 3; CASPASE 7; CURCUMIN; DOXORUBICIN; POLOXAMER; POLYMER; REACTIVE OXYGEN METABOLITE; RESVERATROL; ANTINEOPLASTIC AGENT; DRUG CARRIER; DRUG COMBINATION; MICELLE; STILBENE DERIVATIVE;

ANIMAL CELL; APOPTOSIS ASSAY; ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CELL VIABILITY ASSAY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RELEASE; EMBRYO; ENZYME ACTIVITY; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; NONHUMAN; PARTICLE SIZE; RAT; APOPTOSIS; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; HEART MUSCLE CELL; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDIOTOXICITY; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOXORUBICIN; DRUG CARRIERS; DRUG COMBINATIONS; FEMALE; HUMANS; MICELLES; MYOCYTES, CARDIAC; OVARIAN NEOPLASMS; POLOXAMER; STILBENES;

EID: 84905095582     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24042     Document Type: Article

References (23)

1. Torres V, Simic V,. 2012. Doxorubicin-induced oxidative injury of cardiomyocytes-Do we have right strategies for prevention ? In Cardiotoxicity of oncologic treatments;, Fiuza M, Ed. InTech. Available from: http://www.intechopen.com/books/cardiotoxicity-of-oncologic-treatments/ doxorubicin-induced-oxidative-injury-of-cardiomyocytes-do-we-have-right- strategies-for-prevention-.
2. Deres P, Halmosi R, Toth A, Kovacs K, Palfi A, Habon T, Czopf L, Kalai T, Hideg K, Sumegi B, Toth K,. 2005. Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J Cardiovasc Pharmacol 45 (1): 36-43.
3. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ,. 2009. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119 (1): 99-106.
4. Baur JA, Sinclair DA,. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5 (6): 493-506.
5. Li Y, Cao Z, Zhu H,. 2006. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 53 (1): 6-15.
6. Vinod BS, Maliekal TT, Anto RJ,. 2013. Phytochemicals as chemosensitizers: From molecular mechanism to clinical significance. Antioxid Redox Signal 18 (11): 1307-1348.
7. Liu X, Jiang Z, Han J,. 2012. Increasing solubility of poorly water soluble drug resveratrol by surfactants and cyclodextrins. Adv Mat Res 418-420 (2012): 2231-2234.
8. Walle T,. 2011. Bioavailability of resveratrol. Ann N Y Acad Sci 1215 (1): 9-15.
9. Kurien BT, Singh A, Matsumoto H, Scofield RH,. 2007. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 5 (4): 567-576.
10. Kabanov AV, Alakhov VY,. 2002. Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19 (1): 1-72.
11. Shin HC, Alani AW, Rao DA, Rockich NC, Kwon GS,. 2009. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 140 (3): 294-300.
12. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE,. 2010. Polymeri micelles in anticancer therapy: Targeting, imaging and triggered release. Pharm Res 27 (12): 2569-2589.
13. Wu JM, Hsieh TC,. 2011. Resveratrol: A cardioprotective substance. Ann N Y Acad Sci 1215 (1): 16-21.
14. Stammet M, Kwon GS, Rao DA,. 2010. Drug loading in pluronic(R) micelles made by solvent casting and equilibrium methods using resveratrol as a model drug. J Control Release 148 (1): e50-e51.
15. Ur-Rehman T, Tavelin S, Gröbner G,. 2010. Effect of DMSO on micellization, gelation and drug release profile of Poloxamer 407. Int J Pharm 394 (1-2): 92-98.
16. Chou TC,. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70 (2): 440-446.
17. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A,. 2005. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65 (22): 10183-10187.
18. Iqbal MA, Bamezai RN,. 2012. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 7 (5): e36764.
19. Singh M, Singh N,. 2009. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 325 (1-2): 107-119.
20. Csaki C, Mobasheri A, Shakibaei M,. 2009. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11 (6): R165.
21. Olsson M, Zhivotovsky B,. 2011. Caspases and cancer. Cell Death Differ 18 (9): 1441-1449.
22. Halliwell B, Whiteman M,. 2004. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean ? Br J Pharmacol 142 (2): 231-255.
23. Fiers W, Beyaert R, Declercq W, Vandenabeele P,. 1999. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 18 (54): 7719-7730.